Figure 2
![Figure 2. Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/16/10.1182_blood-2011-03-340166/4/zh89991179180002.jpeg?Expires=1724240734&Signature=QTj1ebqrbFke-B6AYvyHc~8rMV~kjtY3HRWyk7Ob2q~BJqfbKDxV6QCroFRrW5eMEFMcsz5LsmWtEMTW4B5jTE8OwOBQNCAH-WRm7ytmUT5ZZQull89N4gPgqEjsIoZgzKx9qHneHsxIaI5bi~azmCLFqxHJ5j2IZSJPWayS6pc-S5U3kAQeRWp1jw58GWYXqTgzr4o9G6xXHX6XGVxxgStiApy49LbrSpaf7FpsHCgL3B1vmb1yYx5TCFRUyBwP2~-LtZftmrw8xuAhgGzbIkLyYEWOVclEXXKcSKLreZSKseK0r~UaPQOGE1iK53fNA1M-~tojh3U8yX~j8h6OHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).
Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).
